All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
Here, we summarize post-hoc analyses of the TULIP-LTE trial presented at the American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023).
Adults with moderate-to-severe SLE completing the 52-week phase III TULIP-1/TULIP-2 trials reconsented to enroll in the randomized, placebo-controlled, double-blind LTE trial.
From Week 52 through Week 208, the outcomes assessed were:
At Week 208, anifrolumab vs placebo was associated with a:
Figure 1. Post-hoc analyses of the phase III TULIP-LTE trial*
DORIS, Definition of Remission in SLE; LTE, long-term extension; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
*Data from Furie, et al.1; Furie, et al.2; Strand, et al.3; and van Vollenhoven, et al.4
†No placebo patients had available data at Week 208.
The TULIP extension trial of anifrolumab in SLE: 3-year results
At the ACR Convergence 2022, Kalunian presented results from the 3-year extension phase of the TULIP trials. The TULIP-1 and -2 phase III trials investigated anifrolumab, a human IgG1 κ...
Visual abstract | The TULIP trials: Post hoc analysis of sustained glucocorticoid tapering with anifrolumab management of SLE
A visual abstract representing data from a post hoc analysis of the phase III TULIP-1 and TULIP-2 trials (NCT02446912 and...
Subscribe to get the best content related to lupus delivered to your inbox